Navigation Links
Nationally Recognized Glenveigh Medical Announces Orphan Drug Designation for Treatment for Severe Preeclampsia and Eclampsia
Date:2/14/2012

CHATTANOOGA, Tenn., Feb. 14, 2012 /PRNewswire/ -- Glenveigh Medical  announced today that the U.S. Food and Drug Administration (FDA) has granted its request for orphan drug designation for a potential new therapy to treat severe preeclampsia and eclampsia. The compound, digoxin immune fab (ovine), is an existing biologic approved for use in cases of digoxin toxicity. Glenveigh, a nationally renowned life science company, has extensive clinical and in vitro evidence to support continued development of this late-stage opportunity. Preeclampsia occurs in 5-8% of pregnancies in the U.S., and these severe forms are leading causes of maternal and perinatal mortality globally.

"This is a tremendous milestone for our company," stated C. David Adair, M.D., Founder, Chairman, and Chief Scientific Officer of Glenveigh. "As a physician and scientist, I have personally seen the devastation these conditions have caused to both moms and babies.  Our program, which includes two successful Phase II studies, offers hope to patients that there will be a treatment for severe preeclampsia in the near future."

Preeclampsia is a condition in pregnant women that is characterized by high blood pressure and excess protein in the urine in the second and third trimesters of pregnancy. Severe preeclampsia and eclampsia represent the most advanced stages of the disease in which pregnant women can suffer from seizures and organ failure.

"In addition to our patents, orphan designation gives Glenveigh at least 7 years of marketing exclusivity," noted Rick Proctor, President and CEO. "We are delighted that the FDA granted orphan drug designation which gives innovators added incentives to pursue treatments for smaller patient populations."

Eleni Tsigas, Executive Director of the Preeclampsia Foundation, added, "Severe preeclampsia can be life-threatening to mother and baby.  Effective interventions for this serious disorder of pregnancy are lacking. We are thrilled that this designation can better enable further research and development that may lead to a potential therapy."

ABOUT GLENVEIGH MEDICAL | www.glenveigh.com  

Glenveigh Medical is a life science and technology based company focused on advancing the practice of obstetrics. Founded in 2004 by a maternal-fetal medicine specialist, Glenveigh prides itself on bringing innovative solutions to the obstetrics industry, relying upon its scientific and medical advisors to provide guidance on market opportunities that will significantly benefit patients in need. Glenveigh's marketed products include the following medical devices: ebb® (post partum hemorrhage), jetty® (vaginal repairs), and Beacon™ (wireless fetal monitor). Glenveigh is based in Chattanooga, Tennessee.


'/>"/>
SOURCE Glenveigh Medical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Leading Chemical Weapons Preparedness Companies Announce Partnership to Deploy Break-through Diagnostic Test Internationally
2. Masimo Introduces Pronto-7™ Internationally and Lifts Voluntary Recall
3. Medela Announces 2011 Breastfeeding Hall of Excellence Inductees to Nationally Recognize Exceptional Breastfeeding Advocates
4. Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research
5. Reportlinker Adds Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally
6. Medical Simulation Corporation Signs Agreement With a Nationally Ranked Hospital
7. CORD:USE Cord Blood Bank Featured Internationally on CNN en Espanol
8. Internationally Renowned Bariatric and Laparoscopic Surgeons To Meet in San Diego
9. Lilly Recognized as a Top Company for Executive Women
10. The Lanier Law Firms Dana Taschner Recognized Among Southern Californias Top Lawyers
11. nContacts Corporate Website Recognized as Best in Class Medical Site by Interactive Media Council - www.ncontactinc.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):